A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
ALLERGY(2017)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
ALLERGY(2017)